Clinical trials: Advanced Neoplasia
Advanced Solid Tumors
A Phase I Study of AL8326 in Advanced Solid Tumor
1. Main purpose Objective to study the tolerance and safety of single and multiple administration of repeated 28-day cycles of AL8326 in patients with advanced solid tumor, observe the dose limiting toxicity (DLT) and maximum…
- Trial name
- NCT04890587
- Testing
- AL8326 tablets
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Nonsmall Cell Lung Cancer, Adenocarcinoma
cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
The purpose of this study is to evaluate the mutation pattern of epidermal growth factor receptor (EGFR) and other TKI targeted gene during TKI treatment of advanced NSCLC patient with liquid biopsy.
- Trial name
- NCT02980536
- Where
- 9 sites in China
- Volunteers
- 129 people
- Sponsor
- Berry Genomics Co., Ltd.
Non-Small Cell Lung Cancer
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and…
- Trial name
- NCT02364999
- Testing
- Bevacizumab-Pfizer, Bevacizumab-EU, Paclitaxel
- Where
- 263 sites in United States, Australia and 25 more
- Volunteers
- 719 people
- Sponsor
- Pfizer
Lung Cancer
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
Multinational, multi-center medical record review to describe the treatment patterns, clinical outcomes, and EGFR / T790M testing practices in EGFR-mutated advanced NSCLC patients receiving first-line EGFR TKI therapy in Europe.
- Trial name
- REFLECT (NCT04031898)
- Testing
- Non Interventional
- Where
- Bulgaria
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Endometrial Carcinoma
A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma
A clinical trial to evaluate TQB2858 injection combined with Anlotinib Hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial carcinoma
- Trial name
- NCT05121363
- Testing
- TQB2858 injection, Anlotinib Hydrochloride capsules
- Where
- 2 sites in China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer
Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.
- Trial name
- SOLAR (NCT02322593)
- Testing
- TAS-118 plus Oxaliplatin, S-1 plus Cisplatin
- Where
- 6 sites in Japan, South Korea
- Volunteers
- 711 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Neoplasms by Site
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the…
- Trial name
- NCT01629758
- Testing
- Denenicokin, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors, KRAS Mutation; SOS1
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
This is a study in adults with advanced cancer (solid tumours) in whom previous chemotherapy was not successful. Only people who have a tumour with a KRAS mutation can participate in the study.
- Trial name
- NCT04111458
- Testing
- BI 1701963, Trametinib
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 71 people
- Sponsor
- Boehringer Ingelheim
Gynecologic Cancer, Immunotherapy
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation.
- Conditions
- Gynecologic Cancer, Immunotherapy, Gut Microbiome
- Trial name
- NCT04957511
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Viome
Advanced Solid Tumors
SKB103 for Injection in Advanced Solid Tumors
This is a phase 1/2 clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.
- Trial name
- NCT07459998
- Testing
- SKB103 for injection monotherapy
- Where
- 2 sites in China
- Volunteers
- 277 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Solid Tumor, Gynecologic Cancer
A Study of GC203 TIL in Advanced Malignant Solid Tumors
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
- Conditions
- Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer
- Trial name
- KUNLUN-001 (NCT06375187)
- Testing
- Engineering Tumor Infiltrating Lymphocytes
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Malignancies
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
This is a multicenter, open label, first-in-human dose-escalation study of MEDI0680 (AMP-514) to evaluate the safety, tolerability, PK, immunogenicity (IM), and antitumor activity in adult subjects with solid tumors.
- Trial name
- NCT02013804
- Testing
- MEDI0680 (AMP-514)
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- MedImmune LLC
Advanced Non-small Cell Lung Cancer
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants
This multi-year cohort study will assess the real-world safety and effectiveness of first Line (1L) treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC participant subgroups defined…
- Trial name
- NCT06269133
- Testing
- REGN2810, Platinum-doublet chemotherapy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
This is a phase I trial with BYON4228, a humanized monoclonal antibody (mAb) directed against signal regulatory protein (SIRP)α in solid tumors, alone and in combination with pembrolizumab.
- Trial name
- NCT06932952
- Testing
- BYON4228 + Pembrolizumab
- Where
- 6 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Byondis B.V.
Non-squamous Non-small Cell Lung Cancer
A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin® in patients with previously…
- Trial name
- NCT03329911
- Testing
- EU Avastin®, BAT1706, Paclitaxel
- Where
- 5 sites in China, Mexico and 3 more
- Volunteers
- 651 people
- Sponsor
- Bio-Thera Solutions
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts.
- Trial name
- NCT06384352
- Testing
- YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 500 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Non Small Cell Lung Cancer, Breast Cancer
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic…
- Trial name
- NCT05653752
- Testing
- YL202
- Where
- 13 sites in United States, China
- Volunteers
- 80 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumors
Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
This is an open, multiple-dose administration dose exploratory clinical phase I study to evaluate the safety, tolerability, and PK profile of HX009 Injection in patients with advanced solid tumors and to provide a preliminary…
- Trial name
- NCT05731752
- Testing
- HX009
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
Stage IV Renal Cell Carcinoma
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
Single-center, open label, non-randomized, fixed dose-escalation, phase 1 study, performed in ambulatory and day-hospital setting
- Trial name
- NCT00351949
- Testing
- IMP321
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Immutep S.A.S.